Vice President, Asset Team Leader

Arvinas is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer PROteolysis TArgeting Chimeras, or PROTACs, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

This differentiated approach has enabled Arvinas to build a broad pipeline of investigational therapies across oncology and neurodegenerative diseases, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non‑small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non‑Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal bulbar muscular atrophy;

and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer.

Building on its leadership in targeted protein degradation, Arvinas achieved a major milestone in May 2026 with the first‑ever U.S. Food and Drug Administration (FDA) approval of a PROTAC protein degrader therapy. The approval marked a significant advancement for the field and demonstrated the therapeutic potential of targeted protein degradation as a novel treatment modality. This PROTAC has been out‑licensed for commercialization and further development.

#Team Arvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.

We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit  and connect on Linked In and X.

Arvinas is seeking a highly experienced Development Asset Team Leader to apply expert‑level knowledge of biology and the biological mechanisms of drug development to lead cross‑functional development teams that are accountable, in partnership with the functional leaders on the Asset Team, for the scientific strategy and seamless execution of early oncology development programs across all phases of drug development.

The successful candidate will apply deep expertise in biological sciences to recommend and drive the strategy of oncology assets and execution against planned timelines for early, mid‑stage and late‑stage assets. The Development Asset Team Leader will lead a cross‑functional team including clinical research, clinical operations, regulatory affairs, clinical pharmacology, translational/companion diagnostics, CMC, non‑clinical, medical affairs and New Product Planning to deliver against the program strategy.

The successful candidate will have leadership experience across all phases of drug development in the oncology therapeutic area, grounded in a strong foundation in biology.

This role will report to the SVP, Asset Strategy and Team Leadership and can be remote, hybrid, or located at our headquarters in New Haven, CT.

Key responsibilities of this role include, but are not limited to:

• Apply relevant and up-to-date knowledge of biology, biological mechanisms of disease, and drug development to lead drug development strategy creation, lead assets to achieve their development milestones and maximize the overall long‑term value of the assets, which includes:
• Lead the development of long‑range objectives and specify the strategies and actions to achieve them as part of the Integrated Development Plan…